新華製藥(00719.HK)上半年歸母淨利潤升16.12%至20.01億元
格隆匯8月29日丨山東新華製藥股份(00719.HK)公佈2021年中期業績，集團2021年半年度按《中國企業會計準則》計算，實現營業收入為人民幣35.51億元，比去年同期增長8.07%；歸屬於上市公司股東的淨利潤為人民幣20.01億元，比去年同期增長16.12%；董事會建議不派發2021年半年度股息。
上半年，集團克服全球疫情及國際市場動盪、匯率變化、原材料價格上漲、市場競爭加劇等不利因素影響，上下團結一心，搶抓機遇，企業繼續保持了增長的好勢頭，主要經營指標再創歷史新高。
搶抓市場機遇，經營工作實現新突破：
大力推進國際化戰略。積極應對全球經濟和外貿形勢急劇變化，搶抓市場機遇，充分發揮企業綜合優勢，在積極開拓傳統主導產品國際市場的同時，特色原料藥聚卡波非鈣、EPA、卡比多巴、激素產品出口銷量分別增長25%、86%、373%及216.8%，司維拉姆出口實現零突破，出口4.2噸。固體制劑出口英國和歐洲市場7.6億片，同比增長26.05%；ANDA布洛芬片正式出口美國市場，實現出口4,250萬片；羅氏美多芭合作項目正式啟動商業化生產。
加大國內市場開發力度，原料藥國內銷售抓住市場回暖時機，實現銷售收入人民幣4.61億元，同比增長17.44%。其中獸藥新產品卡巴匹林鈣銷售546噸，銷量同比分別增長50%，卡比多巴國內銷售實現零突破。
積極推進大製劑戰略，加大內部改革力度，激發一線營銷人員積極性和創造性，集團製劑產品實現銷售收入人民幣8.24億元，同比增長12.36%，其中十大戰略製劑品種銷量同比增長32.5%。品牌普藥銷售實現較快增長，而布洛芬片國家集採第四批中標，上半年共完成銷售收入人民幣2,973萬元，同比增長90.5%。
實施大研發戰略，科研工作呈現新動力
持續加大研發投入，上半年集團研發投入人民幣1.64億元，同比增長10.28%。上半年集團獲得厄貝沙坦等藥品批件(文號)6個。碳酸司維拉姆原料及製劑完成中美雙報。目前有10個產品在CDE排隊審評。合作研發的抗老年痴呆藥物OAB-14等重點創新藥物進展順利。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
